Watson Pharm receives FDA final approval for Generic Wellbutrin XL 300 Mg

Wed Jun 13, 2007 5:10pm EDT
 
[-] Text [+]
Co announced that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for bupropion hydrochloride extended-release tablets, 300 mg. Bupropion hydrochloride extended-release is the generic equivalent to GlaxoSmithKline's Wellbutrin XL tablets, which is indicated for the treatment of major depressive disorder. The Co intends to launch the product immediately.

 

Editor's Choice

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video
Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better